Androgel (Testosterone) Patent Expiration, LOE Window & CMS Spending

Androgel (Testosterone) by Besins Healthcare Ireland: FDA Orange Book LOE 2026-10-12, 11 AB generics, $4.2M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBesins Healthcare Ireland
FDA Application & PathwayN021015 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2026-10-12
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors11
2024 CMS Total Public Spend$4.2M
2024 Medicare Part D Spend$3.9M
2024 Medicaid Spend$286K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel